| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.01. | QHSLab Posts 25% Increase In Preliminary FY25 Revenue | 1 | RTTNews | ||
| 26.01. | QHSLab reports FY25 preliminary revenue of $2.67M | 2 | Seeking Alpha | ||
| 26.01. | QHSLab, Inc.: QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction | 199 | GlobeNewswire (Europe) | Revenue increased 25% year over year, gross margins expanded to approximately 67%, and convertible debt was substantially eliminatedImproved profitability and early Q-Cog reimbursement activity position... ► Artikel lesen | |
| 23.01. | QHSLab, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | QHSLab, Inc.: QHSLab (OTCQB:USAQ) Initiates Board Expansion Process to Strengthen Governance and Support Next Phase of Growth | 2 | GlobeNewswire (USA) | ||
| QHSLAB Aktie jetzt für 0€ handeln | |||||
| 16.01. | QHSLab, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | QHSLab, Inc.: QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session | 184 | GlobeNewswire (Europe) | Unaudited update reflects revenue growth, positive operating income, removal of convertible debt, and improved cash flow profile entering 2026. Company reports $1.99 million in revenue for the nine... ► Artikel lesen | |
| 06.01. | QHSLab, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.01. | QHSLab wandelt Schulden in Aktien um und verlängert Laufzeit der Anleihe bis 2026 | 2 | Investing.com Deutsch | ||
| 29.12.25 | QHSLab, Inc. (OTCQB:USAQ) Completes $500K Private Placement, Enters 2026 With Clean Capital Structure | 3 | GlobeNewswire (USA) | ||
| 29.12.25 | QHSLab, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | QHSLab, Inc.: QHSLab (OTCQB:USAQ) Announces Launch of Q-Cog to Support Early Detection of Mild Cognitive Impairment and Dementia | 1 | GlobeNewswire (USA) | ||
| 01.12.25 | QHSLab, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.11.25 | QHSLab, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | QHSLab, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 02.09.25 | QHSLab, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.09.25 | QHSLab, Inc.: QHSLab (OTCQB: USAQ) Rolls Out Breakthrough Pediatric Screening Tool Linking Allergies and Mental Health | 1 | GlobeNewswire (USA) | ||
| 14.08.25 | QHSLab, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 16.05.25 | QHSLab, Inc. Signals Strategic Debt Restructuring to Strengthen Balance Sheet and Drive Growth | 288 | GlobeNewswire (Europe) | Company in Advanced Discussions to Restructure Convertible Debt and Unlock Shareholder ValuePotential Agreement Expected to Improve Financial Flexibility and Reduce Dilution Pressure WEST PALM BEACH... ► Artikel lesen | |
| 18.02.25 | QHSLab, Inc. Reports Record Revenue Growth and Positive Net Income in Preliminary Q4 and FY 2024 Financial Results | 188 | GlobeNewswire (Europe) | Four consecutive quarters of year-over-year revenue growth underscore continued business momentum.Revenue surges 98% in Q4 2024 compared to Q4 2023, marking a milestone year for QHSLab.Operational... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | DAX-Konzern Siemens Healthineers legt Zahlen vor | Siemens Healthineers startet solide ins neue Geschäftsjahr und bestätigt den Jahresausblick, wird aber vom schwachen Diagnostikgeschäft in China gebremst. Der DAX-Konzern Siemens Healthineers ist mit... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | ANALYSE-FLASH: Barclays senkt Carl Zeiss Meditec auf 'Equal Weight' | LONDON (dpa-AFX Broker) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | BREAKING: Hims & Hers verschärft Preisdruck bei Novo Nordisk - Aktie beschleunigt Talfahrt | Der dänische Biopharma-Riese ist erst seit wenigen Wochen mit seinem Appetitzügler Wegovy als Tablette auf dem US-Markt und sieht sich einem massiven Preisdruck ausgesetzt. Das Telehealth-Unternehmen... ► Artikel lesen | |
| UNITEDHEALTH | 232,15 | -0,77 % | UnitedHealth: Das sieht gar nicht gut aus | Der enttäuschende Ausblick, den UnitedHealth dem Kapitalmarkt vor Kurzem an die Hand gegeben hat, und maue Aussichten für 2027 hinterlassen weitere Spuren im Aktienkurs des größten US-Krankenversicherers.... ► Artikel lesen | |
| RXSIGHT | 8,390 | +7,29 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen |